{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088680","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.211342+00:00","generated_at":"2026-05-31T09:55:36.209366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theriva Biologics Q2 2024 cash $16.6M, VIRAGE trial to complete enrollment in Q3","bullets":["Cash $16.6M as of June 30, 2024 vs $23.2M at Dec 31, 2023; runway into Q2 2025.","VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.","FDA granted Fast Track Designation for VCN-01 in metastatic pancreatic adenocarcinoma.","Goodwill impairment of $4.0M recorded due to stock price decline and increased discount rate.","R&D expenses $3.0M, G&A $1.5M for Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088680","json":"https://secwatch.observer/filing/0001104659-24-088680.json","markdown":"https://secwatch.observer/filing/0001104659-24-088680.md","text":"https://secwatch.observer/filing/0001104659-24-088680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924088680/0001104659-24-088680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924088680/tm2421314d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:55:36.209366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}